<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="733">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151614</url>
  </required_header>
  <id_info>
    <org_study_id>PRO21230003</org_study_id>
    <nct_id>NCT05151614</nct_id>
  </id_info>
  <brief_title>Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection</brief_title>
  <official_title>Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection: Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Baghdad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Baghdad</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study included 2 arms Colchicine group: Colchicine + standard therapy of COVID-19 Control&#xD;
      group: Standard therapy of COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized controlled trial with 2 arms study trial 1:1 allocation. The&#xD;
      sample size was calculated and we need a total of 160 patients (80 Colchicine add on group&#xD;
      and 80 controls)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Actual">October 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To assess the percentage of cure of the patients</measure>
    <time_frame>up to 14 days</time_frame>
    <description>evauated by normalization of clinical evaluation, laboratory investigations, and imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>- Study the time to recovery</measure>
    <time_frame>up to 14 days</time_frame>
    <description>Evaluated by stay days in hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- to assess side effects seen during the trial</measure>
    <time_frame>up to 14 days</time_frame>
    <description>assessed according clinical evaluation and the appropriate laboratory investigation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>COVID-19 Pandemic</condition>
  <arm_group>
    <arm_group_label>Colchicine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients in this group will receive only standard care which will include all or some of the following, according to the clinical condition of each patient:&#xD;
Acetaminophen 500mg on need&#xD;
Vitamin C 1000mg twice/ day&#xD;
Zinc 75-125 mg/day&#xD;
Vitamin D3 5000IU/day&#xD;
Azithromycin 250mg/day for 5 days&#xD;
Oxygen therapy/ C-Pap if needed&#xD;
Dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed&#xD;
Mechanical ventilation, if needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 0.5 MG</intervention_name>
    <description>Colchicine 0.5 mg tab 1x2 for 1 week then o.5mg tab. 1x1 for another week + the standard therapy ( total duration of colchicine 14 days).</description>
    <arm_group_label>Colchicine group</arm_group_label>
    <other_name>Colchicine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Patients with age above 18 years and of any gender 2. Definite diagnosis of&#xD;
             COVID-19 according to the WHO classification criteria 3. Patients symptomatic for no&#xD;
             more than three days for mild-moderate cases, no more than two days after being severe&#xD;
             cases 4. Understands and agrees to comply with planned study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients refuse to enrol in the study&#xD;
&#xD;
          2. Patients with hypersensitivity to colchicine&#xD;
&#xD;
          3. Patients with chronic diseases: Renal failure with eGFR&lt;30 ml/min; chronic liver&#xD;
             disease with hepatic failure (AST/ALT &gt; 3x normal).; decompensated heart failure, long&#xD;
             QT syndrome (QTc &gt;450 msec.), and uncontrolled arrhythmia; inflammatory bowel disease,&#xD;
             chronic diarrhea or malabsorption; pre-existent progressive neuromuscular disease, and&#xD;
             Metastatic cancer&#xD;
&#xD;
          4. Pregnancy and breast feeding&#xD;
&#xD;
          5. Medications: immunosuppressive chemotherapy; regular use of digoxin, amiodarone,&#xD;
             verapamil or protease inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed S Abdulamir, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alnahrin University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Baghdad</name>
      <address>
        <city>Baghdad</city>
        <country>Iraq</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 27, 2021</last_update_submitted>
  <last_update_submitted_qc>November 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Baghdad</investigator_affiliation>
    <investigator_full_name>Faiq Gorial</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

